Mission:
Autoimmune diseases are the third most common cause of chronic disease in the United States, with an estimated 50 million Americans currently afflicted. I believe that advancing our basic understanding of immune system development will lead to the creation of new therapies for autoimmunity, cancer and infectious disease, much like the majority of treatments currently available. Personally, I advocate for more integrated approaches that combine wet lab work with computational methods. My focus, therefore, is on a systems approach to understanding autoimmunity and infection.
Education and diversity are the cornerstones of scientific progress. We firmly believe in encouraging and training young scientists from all backgrounds, empowering them to discover the cures of tomorrow.
Recently published projects include:
- Why does the transcription factor Aiolos contribute to autoimmunity (in collaboration with Oestreich lab)
- J Immunol. 2024 PMID: 38363226,
- Nat Immunology 2024 PMID: 38049581,
- Nat Communications 2023 PMID: 36964178
- How is DNA damage regulated during lymphocyte development (in collaboration with Oltz lab)
- Nat communications 2020 PMID: 32572033
- Why are gamma-herpesviruses necessary for multiple sclerosis etiology ( in collaboration with Lovett-Racke Lab)
- J Neuroimmunol. 2024, PMID: 39098102
- In silico modeling of infection in model systems (in collaboration w/ MI&I)
- J Clin Invest 2024 PMID: 38833303
- mBio 2023 PMID: 36852995
New projects are:
- How and why is T cell receptor diversity skewed in multiple sclerosis ( in collaboration with Akkaya lab)
- How are anti-insulin B cell receptor positive cells culled during B cell development
